Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter Goon

Showing results (21-30 of 31) with videos related to

Pageof 4
Sort By:
European Journal of Cancer (Oxford, England : 1990)|September 27, 2016
CD8<sup>+</sup> T cell response to human papillomavirus 16 E7 is able to predict survival outcome in oropharyngeal cancerLiam Masterson, Matt Lechner, Sarah Loewenbein, et al.
Scientific Reports|April 20, 2018
Stem cells in middle ear cholesteatoma contribute to its pathogenesisJulia Nagel, Saskia Wöllner, Matthias Schürmann, et al.
The Cochrane Database of Systematic Reviews|February 18, 2014
De-escalation treatment protocols for human papillomavirus-associated oropharyngeal squamous cell carcinomaLiam Masterson, Daniel Moualed, Ajmal Masood, et al.
Current Oncology Reports|March 29, 2022
Viral and Clinical Oncology of Head and Neck CancersPeter Goon, Matthias Schürmann, Felix Oppel, et al.
The Journal of General Virology|April 16, 2005
A functional CD8+ cell assay reveals individual variation in CD8+ cell antiviral efficacy and explains differences in human T-lymphotropic virus type 1 proviral loadBecca Asquith, Angelina J Mosley, Anna Barfield, et al.
British Journal of Cancer|January 8, 2026
Diagnostic accuracy of combinatorial mRNA biomarkers for non-invasive detection and therapy monitoring of oral and oropharyngeal SCCLeonie Hose, Alina Celine Tekin, Bart Verwaaijen, et al.
Molecular Cancer Therapeutics|September 13, 2022
p53 Pathway Inactivation Drives SMARCB1-deficient p53-wildtype Epithelioid Sarcoma Onset Indicating Therapeutic Vulnerability Through MDM2 InhibitionFelix Oppel, Senyao Shao, Sarah Gendreizig, et al.
Blood|February 1, 2003
Low frequency of CD94/NKG2A+ T lymphocytes in patients with HTLV-1-associated myelopathy/tropical spastic paraparesis, but not in asymptomatic carriersMineki Saito, Veronique M Braud, Peter Goon, et al.
Retrovirology|September 21, 2006
Zidovudine plus lamivudine in Human T-Lymphotropic Virus type-I-associated myelopathy: a randomised trialGraham P Taylor, Peter Goon, Yoshitaka Furukawa, et al.
BMC Cancer|January 13, 2023
Primary head and neck cancer cell cultures are susceptible to proliferation of Epstein-Barr virus infected lymphocytesSenyao Shao, Lars Uwe Scholtz, Sarah Gendreizig, et al.
Pageof 4

Showing results (21-30 of 31) with videos related to

Sort By:
Pageof 4
European Journal of Cancer (Oxford, England : 1990)|September 27, 2016
CD8<sup>+</sup> T cell response to human papillomavirus 16 E7 is able to predict survival outcome in oropharyngeal cancerLiam Masterson, Matt Lechner, Sarah Loewenbein, et al.
Scientific Reports|April 20, 2018
Stem cells in middle ear cholesteatoma contribute to its pathogenesisJulia Nagel, Saskia Wöllner, Matthias Schürmann, et al.
The Cochrane Database of Systematic Reviews|February 18, 2014
De-escalation treatment protocols for human papillomavirus-associated oropharyngeal squamous cell carcinomaLiam Masterson, Daniel Moualed, Ajmal Masood, et al.
Current Oncology Reports|March 29, 2022
Viral and Clinical Oncology of Head and Neck CancersPeter Goon, Matthias Schürmann, Felix Oppel, et al.
The Journal of General Virology|April 16, 2005
A functional CD8+ cell assay reveals individual variation in CD8+ cell antiviral efficacy and explains differences in human T-lymphotropic virus type 1 proviral loadBecca Asquith, Angelina J Mosley, Anna Barfield, et al.
British Journal of Cancer|January 8, 2026
Diagnostic accuracy of combinatorial mRNA biomarkers for non-invasive detection and therapy monitoring of oral and oropharyngeal SCCLeonie Hose, Alina Celine Tekin, Bart Verwaaijen, et al.
Molecular Cancer Therapeutics|September 13, 2022
p53 Pathway Inactivation Drives SMARCB1-deficient p53-wildtype Epithelioid Sarcoma Onset Indicating Therapeutic Vulnerability Through MDM2 InhibitionFelix Oppel, Senyao Shao, Sarah Gendreizig, et al.
Blood|February 1, 2003
Low frequency of CD94/NKG2A+ T lymphocytes in patients with HTLV-1-associated myelopathy/tropical spastic paraparesis, but not in asymptomatic carriersMineki Saito, Veronique M Braud, Peter Goon, et al.
Retrovirology|September 21, 2006
Zidovudine plus lamivudine in Human T-Lymphotropic Virus type-I-associated myelopathy: a randomised trialGraham P Taylor, Peter Goon, Yoshitaka Furukawa, et al.
BMC Cancer|January 13, 2023
Primary head and neck cancer cell cultures are susceptible to proliferation of Epstein-Barr virus infected lymphocytesSenyao Shao, Lars Uwe Scholtz, Sarah Gendreizig, et al.
Pageof 4